Great support. A shame we are going to be delayed a few months before commencing NNZ-2591 P2 trials. Approx 129m shares on the register post this raise (including the 3m loan funded shares). I remember someone posted a link to a report valuing ASX biotechs at various stages of their development (P1, P2 and P3 success). I think the average MC of an ASX biotech with P3 success was just over $1b? Could be wrong but if that was the case then we would be approx $7.75 per share. Obvioulsy there are many variables and this is just a back of the envelope calc.
Ann: $3.3 million raised from oversubscribed SPP, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |